Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia

Hepatology Research

Volumn 39, Issue 5, 2009, Pages 439-447

  Morihara, Daisuke ^a   Kobayashi, Masahiro ^a   Ikeda, Kenji ^a   Kawamura, Yusuke ^a   Saneto, Hiromi ^a   Yatuji, Hiromi ^a   Hosaka, Tetuya ^a   Sezaki, Hitomi ^a   Akuta, Norio ^a   Suzuki, Yoshiyuki ^a   Suzuki, Fumitaka ^a   Kumada, Hiromitu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Cirrhosis; Hypersplenism; Interferon; Splenectomy; Thrombocytopenia

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FOLLOW UP; HEMOPERITONEUM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LEUKOCYTE COUNT; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL NEUROPATHY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SPLENECTOMY; SURGICAL TECHNIQUE; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 65449117255     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00481.x     Document Type: Article

References (21)

1. Coon WW. Splenectomy for thrombocytopenia due to secondary hypersplenism. Arch Surg 1988; 123: 369-71.
2. Kishi Y, Sugawara Y, Akamatsu N et al. Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation. Clin Transpl 2005; 19: 769-72.
3. Cescon M, Sugawara Y, Takayama T et al. Role of splenectomy in living-donor liver transplantation for adults. Hepatogastroenterology 2002; 49: 721-3.
4. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
5. Ikeda K, Saitoh S, Kobayashi M et al. Long-term interferon therapy for 1year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. J Gastroenterol Hepatol 2001; 16: 406-15.
6. Hayashi PH, Mehia C, Joachim Reimers H, Solomon HS, Bacon BR. Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. J Clin Gastroenterol 2006; 40: 740-4.
7. Hassab MA, Younis MT, el-Kilany MS. Gastroesophageal decongestion and splenectomy in the treatment of esophageal varices secondary to bilharzial cirrhosis: Anatomical and experimental studies. Surgery 1968; 63: 731-7.
8. Kaplan EL. Nonparametric estimation for incomplete observation. J Am Stat Assoc 1958; 53: 457-81.
9. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 248-75.
10. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 -June 10-12, 2002. Hepatology 2002; 36: S3-20.
11. Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23: 1055-65.
12. Shimada M, Hashizume M, Shirabe K, Takenaka K, Sugimachi K. A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism. Performing a hepatectomy after a laparoscopic splenectomy. Surg Endosc 2000; 14: 127-30.
13. Kercher KW, Carbonell AM, Heniford BT, Matthews BD, Cunningham DM, Reindollar RW. Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. J Gastrointest Surg 2004; 8: 120-6.
14. Chen XP, Wu ZD, Huang ZY, Qiu FZ. Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg 2005; 92: 334-9.
15. Yao YM, Liu QG, Yang W, Zhang M, Ma QY, Pan CE. Effect of spleen on immune function of rats with liver cancer complicated by liver cirrhosis. Hepatobiliary Pancreat Dis Int 2003; 2: 242-6.
16. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-81.
17. Tomikawa M, Hashizume M, Akahoshi T et al. Effects of splenectomy on liver volume and prognosis of cirrhosis in patients with esophageal varices. J Gastroenterol Hepatol 2002; 17: 77-80.
18. Moreno MG, Muriel P. Remission of liver fibrosis by interferon-alpha 2b. Biochem Pharmacol 1995; 50: 515-20.
19. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
20. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
21. McHutchison JG, Dusheiko G, Shiffman ML et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-36.